Study investigators cautioned against routine use of the device in complex percutaneous coronary interventions and to treat ...

The results challenge the rapid growth of Impella support during high-risk PCI. Investigators say a reckoning is needed.

High-risk patients with left ventricular dysfunction fare as well, or better, without the support of a microaxial flow pump ...

Randomized trials neutral for pump device in complex elective cases, STEMI with reperfusio ...

This screenshot from an Abiomed video demonstrates placement of the Impella 2.5 and Impella CP. Delivered in a minimally invasive way, Impella pumps actively unload the heart, aiding native heart ...

Johnson & Johnson (NYSE:JNJ) reported results from the randomized STEMI DTU trial of its Impella CP device at ACC 2026. The ...

WASHINGTON, DC—A protocol focusing on early use of the Impella ventricular support device (Abiomed) in patients with acute MI complicated by cardiogenic shock may help lower the stubbornly high ...

DANVERS, Mass.--(BUSINESS WIRE)--Data from more than 1,000 patients presented during the virtual 2020 Society for Cardiovascular Angiography & Interventions (SCAI) Scientific Sessions demonstrates ...

PHILADELPHIA -- The Impella mechanical support device, frequently used in patients in cardiogenic shock who are undergoing percutaneous coronary interventions, was more expensive than intra-aortic ...

BOSTON--(BUSINESS WIRE)--Abiomed (ABMD) announces the result of a three-year, investigator-led study of all Impella-supported patients treated at 109 hospitals in Japan shows a 30-day survival rate of ...

PHILADELPHIA — Interventional cardiology has taken quite a shine to Impella ventricular assist pumps (Abiomed) for cardiogenic shock (CS) and to support high-risk procedures, but two new observational ...